S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
NASDAQ:RCM

R1 RCM (RCM) Stock Price, News & Analysis

$12.47
-0.31 (-2.43%)
(As of 04/12/2024 ET)
Today's Range
$12.31
$12.75
50-Day Range
$10.35
$14.58
52-Week Range
$8.87
$18.70
Volume
1.90 million shs
Average Volume
2.45 million shs
Market Capitalization
$5.24 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.87

R1 RCM MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.62 Rating Score
Upside/​Downside
35.3% Upside
$16.87 Price Target
Short Interest
Healthy
7.95% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.33
Upright™ Environmental Score
News Sentiment
0.27mentions of R1 RCM in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$143,959 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.04) to $0.15 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.69 out of 5 stars

Business Services Sector

16th out of 306 stocks

Management Services Industry

1st out of 5 stocks

RCM stock logo

About R1 RCM Stock (NASDAQ:RCM)

R1 RCM Inc. provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers. The company also offers modular solutions, including functional partnership, an outsourcing solutions for improvements across targeted revenue cycle areas for hospital and physician group customers; revenue recovery, to fast-track payer and patient cash collections; revenue optimization, a solution to uncover missed or underreported revenue; clinical integrity, used to improve documentation and coding accuracy to maximize earned revenue for the services provided; and regulatory navigation, a compliance-first solutions for government reimbursement accuracy, pharmacy savings, and compliance. The company was incorporated in 2003 and is headquartered in Murray, Utah.

RCM Stock Price History

RCM Stock News Headlines

R1 RCM (NASDAQ:RCM) Rating Reiterated by KeyCorp
Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Vista takes Model N private for $1.25B
Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Truist Financial Reaffirms Their Hold Rating on R1 RCM (RCM)
Analyst Scoreboard: 12 Ratings For R1 RCM
RCM Apr 2024 20.000 call
See More Headlines
Receive RCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for R1 RCM and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/16/2023
Today
4/13/2024
Next Earnings (Confirmed)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Management services
Sub-Industry
Health Care Services
Current Symbol
NASDAQ:RCM
CUSIP
00438V10
Employees
30,000
Year Founded
2003

Price Target and Rating

Average Stock Price Target
$16.87
High Stock Price Target
$22.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+35.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.64
Research Coverage
13 Analysts

Profitability

Net Income
$3.30 million
Pretax Margin
0.93%

Debt

Sales & Book Value

Annual Sales
$2.25 billion
Cash Flow
$0.67 per share
Book Value
$6.56 per share

Miscellaneous

Free Float
264,776,000
Market Cap
$5.24 billion
Optionable
Optionable
Beta
0.78

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Lee RivasMr. Lee Rivas (Age 49)
    CEO & Director
    Comp: $1.12M
  • Mr. John M. SparbyMr. John M. Sparby (Age 48)
    President
    Comp: $656.99k
  • Ms. Jennifer Williams (Age 47)
    Executive VP, CFO & Treasurer
  • Ms. Pamela L. Spikner (Age 47)
    Principal Accounting Officer & Chief Accounting Officer
  • Evan Smith C.F.A.
    Senior Vice President of Finance & Investor Relations
  • Mr. Corey Perman
    Executive Vice President of Compliance & Risk
  • Mr. Sean Radcliffe
    Executive VP, General Counsel & Corporate Secretary
  • Ms. Kate Sanderson
    Executive VP & Chief Human Resources Officer
  • Mr. David Strickle
    Executive Vice President of Integration
  • Mr. Kyle A. Hicok (Age 44)
    Executive VP & Chief Commercial Officer

RCM Stock Analysis - Frequently Asked Questions

Should I buy or sell R1 RCM stock right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for R1 RCM in the last year. There are currently 5 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RCM shares.
View RCM analyst ratings
or view top-rated stocks.

What is R1 RCM's stock price target for 2024?

13 equities research analysts have issued 1 year price objectives for R1 RCM's shares. Their RCM share price targets range from $11.00 to $22.00. On average, they predict the company's share price to reach $16.87 in the next twelve months. This suggests a possible upside of 35.3% from the stock's current price.
View analysts price targets for RCM
or view top-rated stocks among Wall Street analysts.

How have RCM shares performed in 2024?

R1 RCM's stock was trading at $10.57 at the beginning of 2024. Since then, RCM stock has increased by 18.0% and is now trading at $12.47.
View the best growth stocks for 2024 here
.

When is R1 RCM's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our RCM earnings forecast
.

How can I listen to R1 RCM's earnings call?

R1 RCM will be holding an earnings conference call on Wednesday, May 8th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were R1 RCM's earnings last quarter?

R1 RCM Inc. (NASDAQ:RCM) announced its earnings results on Thursday, February, 16th. The healthcare provider reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.03) by $0.06. The healthcare provider earned $532.80 million during the quarter, compared to analyst estimates of $519.28 million. R1 RCM had a net margin of 0.15% and a trailing twelve-month return on equity of 0.12%. The firm's quarterly revenue was up 33.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.11 EPS.

What ETFs hold R1 RCM's stock?
What guidance has R1 RCM issued on next quarter's earnings?

R1 RCM issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.6 billion-$2.7 billion, compared to the consensus revenue estimate of $2.7 billion.

What is Joseph Flanagan's approval rating as R1 RCM's CEO?

253 employees have rated R1 RCM Chief Executive Officer Joseph Flanagan on Glassdoor.com. Joseph Flanagan has an approval rating of 70% among the company's employees.

What other stocks do shareholders of R1 RCM own?

Based on aggregate information from My MarketBeat watchlists, some companies that other R1 RCM investors own include NVIDIA (NVDA), JD.com (JD), Baozun (BZUN), Inseego (INSG), BioXcel Therapeutics (BTAI), Marvell Technology (MRVL), Akoustis Technologies (AKTS), Alibaba Group (BABA), Bilibili (BILI) and Model N (MODN).

How do I buy shares of R1 RCM?

Shares of RCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does R1 RCM have any subsidiaries?
The following companies are subsidiares of R1 RCM: Accretive Health Mauritius Inc., Cerner RevWorks, Clearsight Intermediate Holdings Inc., Cloudmed, Flare Capital Partners Investment Company, Intermedix, Intermedix ARM LLC, Intermedix Corporation, Intermedix Holdings Inc., Intermedix Lietuva UAB, Intermedix Midco Inc., Intermedix Office Based LLC, Intermedix Staffing Inc., Medical Consultants Inc., Practice Support Resources LLC, Project Links Parent Inc., Project Roadrunner Merger Sub Inc., Project Roadrunner Parent Inc., R1 RCM Global Private Limited, R1 RCM India Private Limited, Rover16 Inc., SCHEDULING.COM INC., SCI Solutions, Tonic Health LLC, VisitPay, cGate Health Inc., and iVinci Partners LLC.
Read More
This page (NASDAQ:RCM) was last updated on 4/14/2024 by MarketBeat.com Staff

From Our Partners